FURTHER, Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc’s breakthrough hepatitis C drug Sovaldi a patent in India. Tatas likely to invest another Rs 2,000 crore in their loss-making wireless telephony firm as equity within the next two years to service its loans.
Trend in FII flows: The FIIs were net buyers of Rs.342cr in the cash segment on Thursday while the domestic institutional investors (DIIs) were net buyers of Rs. 13cr, as per the provisional figures released by the NSE.
0 comments:
Post a Comment